The anterior cruciate ligament is the most commonly injured ligament, with up to 10% of surgery failure. Atraumatic instability in the early postoperative period (<6 months) occurs as the result of poor surgical technique, failure of graft integration, or early mechanical overload during rehabilitation. Engineered cell therapy is a developing resource designed to increase the rate of tendon-to-bone interface healing. We describe a simple and safe technique to harvest mesenchymal stem cells by arthroscopic bone marrow aspiration from the intercondylar notch.
T he anterior cruciate ligament (ACL) is the most commonly injured ligament in the knee, with an up to 10% rate of surgery failure. 1 Atraumatic recurrent instability in the early postoperative period (<6 months) occurs as the result of poor surgical technique, failure of graft integration, or early mechanical overload during rehabilitation. 2 Engineered cell therapy is a developing resource designed to increase the rate of tendon-to-bone incorporation. The isolation of connective tissue progenitor cellsdwhich are stem cells with the capability of selfrenewal; multilineage differentiation; and formation of terminally differentiated cells such as tendons, cartilages, and ligamentsdis performed from bone marrow aspiration. Bone marrow stem cells assist in graft osteointegration by overexpressing transforming growth factor beta 1 proteins, the most important fibrotic inducer and an ossification promoter. 3 Usually, the performance of bone marrow aspiration is at the iliac crest. Despite being secure and effective, a technique at an anatomical site that implies less morbidity, infection potential, and surgical time it is preferred. Therefore, we describe an efficient 3-stage procedure (Fig 1) to harvest connective tissue progenitor cells from the intercondylar notch.
Surgical Technique
After approval from the ethical and institutional review board, patients were eligible for inclusion only after giving their permission to participate through a signed informed consent.
Preparation and Positioning
With the patient placed supine on the operating room table, and after the induction of anesthesia, we conduct bilateral stability and range-of-motion tests. Before preparation and sterile draping of the lower limb, we support the placement of a well-padded, high-thigh nonsterile tourniquet, and if using a leg post, shifting the patient closer to produce a proper valgus when needed. After sterile drape, an assistant drops the end of the bed, allowing a 90 flexion. 
Bone Marrow Cell Harvest
Video 1 and Figure 2 show how before drilling the femoral and tibial tunnels, we insert a 14-gauge trocar (Bone Marrow Aspirate kit; Arthrex, Naples, FL) through the anteromedial portal, and when the tip of the device is at the desired entry point, we introduce the trocar at an approximately 30 mm depth, turning it clockwise. Our desire entry point is at the femoral notch apex, usually at the center of the femur or 5 mm lateral to the lateral edge of the posterior cruciate ligament insertion. After inserting the trocar, an assistant turns off the arthroscopic fluid, and we remove the stylet and attach a 10-mL syringe to discard the first milliliter of the aspirated bone marrow. Then, with a 30-mL syringe preloaded with 4 mL of a heparinized solution (5 mL of 1000 IU/mL of sodium heparin þ 5 mL of sterile saline þ 8 mL of anticoagulant citrate dextrose), we slowly aspirate bone marrow, turning the trocar 90 clockwise every 2 mL and withdrawing the needle 0.5 cm every 8 mL until obtaining 60 mL of bone marrow to process it in the Arthrex Angel cPRP & Bone Marrow Processing System. On average, bone marrow harvesting is a 10-minute procedure.
Preparation of Leukocyte and Platelet Concentrate from Bone Marrow Aspirate
After properly assembling the Arthrex Angel cPRP & Bone Marrow Processing System with a 20-mL syringe attached to the platelet-rich plasma port, we introduce the blood mixed with the heparinized solution into the whole blood compartment and adjust the volume of blood to 60 mL for the software to set an adequate centrifugation time and force. At the end of the centrifugation cycle, the blood components will pass through a platelet sensor that uses wavelengths to separate the concentrated red cells and platelet-poor plasma into its respective compartments and the leukocyte-poor, platelet-rich plasma into the attached syringe.
Biological Augmentation of the Graft
After arthroscopic confirmation of a satisfactory ACL reconstruction, the femoral tunnel, the tibial tunnel, and the graft are augmented with platelet-rich plasma at 7% (Angel cPRP & Bone Marrow Processing System; Arthrex) through an intraarticular injection. 
Discussion
We had a 30% rate of mild adverse events at short-term follow-up and have not experienced reinterventions or reports of severe complications such as intraoperative fractures, deep-vein thrombosis, or infections (superficial incisional, deep incisional, or septic arthritis). Also, we found a significantly greater surgical time in the intervention group when compared with the control group (50 AE 8 minutes in the control group vs 65 AE 11 minutes in the bone marrow group; P < .01). To our knowledge, these are the first rates of adverse events reported with this technique.
Mesenchymal stem cells have received much attention as an engineered cell therapy because of the diversity and high concentration of growth factors they possess, making them a promising regenerative approach in various musculoskeletal tissues such as ACL reconstructions, the most performed treatment for ACL rupute. 4, 5 Although many patients report excellent results with the procedure, 37% remain with instability and 42% to 90% have osteoarthritis during the next 12 years, 6 which has stimulated the research of biological processes to achieve a faster tendon to bone healing and acquisition of native ligament properties in the graft.
However, some clinical outcomes with the use of biological adjuvantsdsuch as the time of graft maturation assessed by magnetic resonance imaging and histologydare contradictory. [7] [8] [9] In our experience, we had a slightly lower rate of mild adverse events at short-term follow-up than the reported by Beitzel et al., 10 and all the complications found were the most commonly reported during standard ACL reconstructions (without arthroscopic bone marrow aspirate), 11 making an association with the previously described procedure very unlikely. Moreover, recent analysis suggests that these complications have weak evidence for association with return to sport. 12 To date, we have performed the procedure in a small sample of 23 patients, which makes the difference in surgical time very likely be due to a type II error.
Although the outcomes of adverse events and surgical time differences are not the subject of discussion in this article, we believe it is of the utmost importance to briefly inform the reader about the data in which we base our judgment to support as a safe procedure the bone marrow aspirate through the anteromedial portal during ACL reconstruction.
As our outcomes and the contradictions reported in the literature can be due to several factors, such as small series, little statistical validity, or high treatment heterogeneity, we believe that a safe and reproducible technique ( Table 1) would help in the realization of better-quality studies to help to determine the real value of the engineered cell therapy. The aforementioned approach can be done during the ACL reconstruction from the same standard arthroscopic portals and has a negligible learning curve ( Table 2 ). The only limitation we could argue is the increase in surgical time ( Table 3 ). In conclusion, the bone marrow Table 2 . Surgical Pearls and Pitfalls of Arthroscopic Intercondylar Notch Bone Marrow Aspiration During Anterior Cruciate Ligament Reconstruction aspiration from the femoral intercondylar notch during an ACL reconstruction is safe and reproducible. Nevertheless, the surgical time increases significantly.
